Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.
GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
In the wake of Achaogen's bankruptcy, experts discussed ways to ensure new treatments are available to combat drug-resistant bacteria that threaten a post-antibiotic world.
Drug discovery and development company Scynexis, which is in midstage clinical development of a novel hepatitis C treatment, is getting closer to reaching its $15 million fundraising target. Scynexis has raised nearly $11.5 million so far, according to an amended securities filing. The fundraiser, a mix of equity, debt, options and warrants, launched in December. […]
Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. PowerPoint presentations. After 11 minutes on stage, another presenter took their place. Immunotherapy company Heat Biologics broke from script and announced a $10 million series B round to complete one mid-stage study on its lead treatment candidate and two early […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Drug discovery and development firm Scynexis, which is moving forward on a new hepatitis C treatment, has raised $5 million in a fundraising effort targeted to reach up to $15 million. A total of nine investors have invested in the round that is a combination of equity, debt, warrants and options, according to securities filings. […]